ERBB2 and breast cancer: In the large meta-analysis (n = 11,955) of the Collaborative Trials in Neoadjuvant Breast Cancer (CTNeoBC) led by Cortazar and colleagues, patients with early BC who achieved a pathological complete response (pCR) after NAC had better long-term survival than patients with residual disease, and this association was even more pronounced in patients with more aggressive subtypes, namely triple-negative BC (TNBC) and HER2-positive (HER2+), hormone receptor-negative tumours [4].